Asset·Oral peptide/small molecule peptide

Lotiglipron

Aliases: PF-07081532 · oral GLP-1 small molecule

Lotiglipron is a oral peptide/small molecule peptide targeting GLP-1R, developed by Pfizer for multiple indications. As of Aug 15, 2024, its highest verified stage is Discontinued.

Discontinued· verified Aug 15, 2024

Identity

Generic name: lotiglipron
Brand names: —
Development codes: PF-07081532
Sponsor / originator: Pfizer
Targets: GLP-1R
Route / formulation: Oral tablet

Development timeline

Discontinued· Type 2 diabetes· Global
As of Aug 15, 2024 · Confidence: high
Source: Pfizer provides update on phase 2 oral GLP-1 program: discontinuation of lotiglipronPfizer discontinued lotiglipron due to asymptomatic transaminase elevations observed in phase 2.

Trials

View all →

Registry ID	Phase	Status	Enrollment	Completion
Pfizer-lotiglipron-Ph2	Phase 2	Terminated	200	Jun 26, 2023

Sources

registryprimary record
A study to evaluate safety, tolerability, PK/PD of AMG 133 in adults with obesity
Amgen Inc. · ClinicalTrials.gov · Apr 4, 2018 · NCT03548935
company-releaseprimary record
Pfizer provides update on phase 2 oral GLP-1 program: discontinuation of lotiglipron
Pfizer Inc. · Pfizer Press Release · Jun 26, 2023